Ukraine charges 27 in a falsified tirzepatide manufacturing ring

Prosecutors in Ukraine's Dnipropetrovsk region, working with the Security Service of Ukraine, have served notices of suspicion on 27 people accused of running a large-scale scheme to manufacture and sell a falsified weight-loss drug marketed as "Biopatid" ^[1]. The product contained tirzepatide, the active ingredient in Mounjaro and Zepbound, but was made without any government approval, registration, or quality testing ^[1].

According to the prosecutors' account, the raw tirzepatide came from China and was imported through a customs broker who falsely declared it as a food additive to avoid inspection ^[1]. Once inside Ukraine, the material was mixed with other ingredients in an unlicensed lab and packaged as Biopatid, which was then marketed to cosmetology clinics, doctors, bloggers, and other public figures across the country ^[1]. Investigators say basic materials cost about $17 per unit while the finished product sold for as much as $1,200, and that more than $5 million worth of the drug has been produced since the start of the year ^[1]. More than 250 searches were carried out at labs, storage sites, clinics, and hospitals, turning up lab equipment, packaging materials, and roughly 15 million hryvnias in cash, along with expensive cars and other assets ^[1]. Prosecutors say the group knew of adverse reactions among users but kept selling the drug anyway, and that one suspect who owned a well-known Kyiv clinic promoted the product to colleagues and at professional trainings ^[1]. The investigation is ongoing, and authorities are still trying to identify everyone harmed by the drug ^[1].

The Ukraine case is not an isolated one. In Brazil, customs agents have found tirzepatide and semaglutide products smuggled in shoe soles, vehicle compartments, and even jars of dulce de leche, with more than 76,000 injection pens and vials seized in the first half of 2026 alone — nearly three times the total for all of 2025 ^[2]. Reuters reporting cited in that story estimated that compounded and smuggled products make up about 51% of Brazil's roughly $7 billion weight-loss drug market, with unauthorized tirzepatide selling for as little as $75 for a six-week supply versus hundreds of dollars for approved medicines ^[2]. Brazilian authorities have logged 83 deaths and more than 3,600 health complications tied to weight-loss products since 2018, though those figures span many different products and circumstances ^[2].

Why it matters for patients

Neither the Ukraine case nor the Brazil reporting involves the U.S. supply chain directly, but both illustrate the same pattern driving counterfeit activity worldwide: high demand and high prices for approved GLP-1 drugs create an opening for unregulated versions with no verified ingredients, purity, dosing, or storage conditions ^{[1] [2]}. Prosecutors in Ukraine allege the sellers knew of adverse reactions and continued distributing the product anyway, and doctors quoted in the Brazil reporting described patients needing intensive care or developing severe symptoms after using unauthorized tirzepatide products ^{[1] [2]}. For U.S. patients, the takeaway is that a low price or unfamiliar seller for a GLP-1 product, especially one obtained outside a licensed pharmacy, does not guarantee the product actually contains what it claims, in the amount claimed.

What happens next

Ukrainian authorities say the pre-trial investigation is continuing, including efforts to trace all raw-material supply channels, the full volume of product made and sold, and the people who may have been harmed ^[1]. Decisions on pretrial detention or other measures for the 27 suspects were still pending as of the September 13, 2026 announcement ^[1]. No timeline for charges or trial has been set in the public record reviewed here.